Eli Lilly Licenses Amylin Diabetes Treatment in US$325 M Deal
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 29 (Table of Contents)
Published: 2 Oct-2002
DOI: 10.3833/pdr.v2002.i29.991 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Eli Lilly signed a global licensing and co-development agreement with Amylin Pharmaceuticals for AC2993 for the treatment of type 2 diabetes...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS